Literature DB >> 32067819

First magnetic resonance imaging-guided cardiac radioablation of sustained ventricular tachycardia.

Michael Mayinger1, Boldizsar Kovacs2, Stephanie Tanadini-Lang1, Stefanie Ehrbar1, Lotte Wilke1, Madalyne Chamberlain1, Amanda Moreira1, Nienke Weitkamp1, Corinna Brunckhorst2, Firat Duru2, Jan Steffel2, Alexander Breitenstein2, Hatem Alkadhi3, Helena I Garcia Schueler1, Robert Manka4, Frank Ruschitzka2, Matthias Guckenberger1, Ardan M Saguner2, Nicolaus Andratschke1.   

Abstract

PURPOSE: To report the feasibility of magnetic resonance imaging-guided cardiac single fraction radioablation (MRgRA) in a patient with dilated cardiomyopathy and recurrent sustained ventricular tachycardia (VT) leading to electrical storms (ES). MATERIALS/
METHODS: A workflow to perform Stereotactic Arrhythmia Radioablation (STAR) on a hybrid MR-Linac with real-time tracking and beam-gating was established. Challenges of the MRgRA approach included: (a) the safety of a non-MR compatible cardiac implantable electronic device (CIED) in the MR-Linac field, (b) artefacts caused by the CIED and (c) respiratory motion management with cine-tracking of the moving heart. The specific absorption rate and slew rate of the MR-Linac were within the specifications of a MR-conditional CIED. Phantom measurements showed CIED distortion artefacts of less than 1.5 mm. During MR simulation, tracking could be established on the upper liver to avoid interference with the moving heart and CIED extinction artefacts. Areas of anatomical scarring and critical substrate were identified using invasive three-dimensional electroanatomical mapping of the clinical VT during electrophysiological studies and cardiac MR imaging/computed tomography to build a volumetric target.
RESULTS: A 71-year-old male patient with non-ischemic dilated cardiomyopathy and recurrent therapy-refractory sustained VT with repetitive implantable cardioverter-defibrillator (ICD) shocks was treated with a single fraction of 25 Gy @85% isodose, cine-tracking time was 46 min, beam-on time 24 min. 24 h post intervention the patient developed an aggravation of the clinical VT and prolonged ES. VT ceased following high-dose dexamethasone administration after 48 h. After this point, the patient remained without any episodes of sustained ventricular tachyarrhythmia requiring ICD interventions until the last follow-up at three months.
CONCLUSION: Real-time tracking and beam-gating were successfully applied in this first MRgRA to treat sustained VT.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MR-Linac; Noninvasive; Radioablation; Stereotactic radiotherapy; Ventricular tachycardia

Mesh:

Year:  2020        PMID: 32067819     DOI: 10.1016/j.radonc.2020.01.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

Review 1.  Stereotactic Ablative radiation therapy (SABR) for cardiac arrhythmia: A new therapeutic option?

Authors:  Alba Fiorentino; Fabiana Gregucci; Ilaria Bonaparte; Nicola Vitulano; Alessia Surgo; Rosario Mazzola; Antonio Di Monaco; Roberta Carbonara; Filippo Alongi; Tommaso Langialonga; Massimo Grimaldi
Journal:  Radiol Med       Date:  2020-05-13       Impact factor: 3.469

2.  Dosimetric feasibility of stereotactic ablative radiotherapy in pulmonary vein isolation for atrial fibrillation using intensity-modulated proton therapy.

Authors:  Xue-Ying Ren; Peng-Kang He; Xian-Shu Gao; Zhi-Lei Zhao; Bo Zhao; Yun Bai; Si-Wei Liu; Kang Li; Shang-Bin Qin; Ming-Wei Ma; Jing Zhou; Yi Rong
Journal:  J Appl Clin Med Phys       Date:  2021-04-04       Impact factor: 2.102

3.  Proof-of-concept for x-ray based real-time image guidance during cardiac radioablation.

Authors:  Nicholas Hindley; Suzanne Lydiard; Chun-Chien Shieh; Paul Keall
Journal:  Phys Med Biol       Date:  2021-08-24       Impact factor: 3.609

4.  MR-guided stereotactic body radiation therapy for primary cardiac sarcomas.

Authors:  Stefanie Corradini; Rieke von Bestenbostel; Angela Romano; Adrian Curta; Dorit Di Gioia; Lorenzo Placidi; Maximilian Niyazi; Luca Boldrini
Journal:  Radiat Oncol       Date:  2021-03-26       Impact factor: 3.481

5.  Case Report: A Case Report of Stereotactic Ventricular Arrhythmia Radioablation (STAR) on Large Cardiac Target Volume by Highly Personalized Inter- and Intra-fractional Image Guidance.

Authors:  Maria Lucia Narducci; Francesco Cellini; Lorenzo Placidi; Luca Boldrini; Francesco Perna; Gianluigi Bencardino; Gaetano Pinnacchio; Roberta Bertolini; Giorgio Cannelli; Vincenzo Frascino; Luca Tagliaferri; Silvia Chiesa; Gian Carlo Mattiucci; Mario Balducci; Maria Antonietta Gambacorta; Marco Rossi; Luca Indovina; Gemma Pelargonio; Vincenzo Valentini; Filippo Crea
Journal:  Front Cardiovasc Med       Date:  2020-11-23

6.  Feasibility of an Automatic Ultrasonographic Image Acquisition System Associated With an Artificial Intelligence Algorithm for Real-Time Monitoring of Cardiac Motion During Cardiac Radio-Ablation.

Authors:  Matteo Casula; Veronica Dusi; Saskia Camps; Jérémie Gringet; Tristan Benoit; Adriano Garonna; Roberto Rordorf
Journal:  Front Cardiovasc Med       Date:  2022-04-25

7.  Case Report: Repeated Stereotactic Radiotherapy of Recurrent Ventricular Tachycardia: Reasons, Feasibility, and Safety.

Authors:  Jana Haskova; Petr Peichl; Marek Šramko; Jakub Cvek; Lukáš Knybel; Otakar Jiravský; Radek Neuwirth; Josef Kautzner
Journal:  Front Cardiovasc Med       Date:  2022-03-28

Review 8.  Stereotactic Radiotherapy: An Alternative Option for Refractory Ventricular Tachycardia to Drug and Ablation Therapy.

Authors:  Wenfeng Shangguan; Gang Xu; Xin Wang; Nan Zhang; Xingpeng Liu; Guangping Li; Gary Tse; Tong Liu
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

9.  Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia: Single Center First Experiences.

Authors:  Ian J Gerard; Martin Bernier; Tarek Hijal; Neil Kopek; Piotr Pater; Jordan Stosky; Gabriela Stroian; Bruno Toscani; Joanne Alfieri
Journal:  Adv Radiat Oncol       Date:  2021-04-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.